The Amendment is better than the original release.
Post# of 30027
(Total Views: 453)
Posted On: 11/05/2018 4:41:22 PM
The Amendment is better than the original release.
It clarifies and explains more.
The take that it's bad or worse or final or locked is just not the case.
One could have said they were losing Elto, up until they didn't lose Elto.
All things are negotiable, as they have been over the past 4 years.
It is not easy.
GC has kept us on the field and the next step is by Dec. 15 an agreement and a merger of Elto and another company.
That is, if that date needs to be moved back a bit or if it's completed before that date.
There's a plan. Each step forward is a step closer to a very healthy much stronger company.
" an independent third-party valuation report which valued the Parkinson's disease levodopa-induced dyskinesia (PD-LID) indication for Eltoprazine in the US and Europe at $316 million."
I can't imagine them megering with another company that has zero to add to the combined company.
Again, the amendment was a good thing.
Aloha
It clarifies and explains more.
The take that it's bad or worse or final or locked is just not the case.
One could have said they were losing Elto, up until they didn't lose Elto.
All things are negotiable, as they have been over the past 4 years.
It is not easy.
GC has kept us on the field and the next step is by Dec. 15 an agreement and a merger of Elto and another company.
That is, if that date needs to be moved back a bit or if it's completed before that date.
There's a plan. Each step forward is a step closer to a very healthy much stronger company.
" an independent third-party valuation report which valued the Parkinson's disease levodopa-induced dyskinesia (PD-LID) indication for Eltoprazine in the US and Europe at $316 million."
I can't imagine them megering with another company that has zero to add to the combined company.
Again, the amendment was a good thing.
Aloha
(3)
(0)Amarantus Bioscience Holdings (AMBS) Stock Research Links
Scroll down for more posts ▼